📰 Full Story
Medtronic plc said on Feb. 3, 2026 it will exercise an option to acquire Israeli diagnostics firm CathWorks for up to $585 million, with additional milestone/earn-out payments possible.
The deal—announced from Medtronic’s Galway, Ireland office—builds on a 2022 co-promotion agreement for CathWorks’ AI-driven FFRangio system, which derives fractional flow reserve (FFR) from routine angiograms to assess coronary physiology.
Closing is subject to customary regulatory approvals, including review by the U.S. Federal Trade Commission, and is expected by the end of Medtronic’s fiscal 2026.
Medtronic said the purchase should be immaterial to GAAP and adjusted EPS in fiscal 2027 and neutral-to-accretive thereafter.
The announcement coincided with active institutional positioning in Medtronic stock: Cullen Capital trimmed its stake by about 1.1% (29,045 shares sold, per a Feb. 5 filing), Davidson Investment Advisors sold 1,752 shares (Feb. 4), while Zurich Cantonalbank added roughly 60,930 shares (Feb. 4). Analysts have flagged the deal as a strategic bolt-on that could expand recurring software and diagnostics revenue streams for Medtronic’s cardiovascular portfolio.























💬 Commentary